Largest UK RWE Study of Sequenced 2nd Generation TKIs in CML
11 December 2019
- This weekend at the 61st American Society of Haematology Annual Meeting and Exposition in Orlando, Florida, SVMPharma and Incyte’s study on chronic myeloid leukaemia (CML) was presented as a poster.
- This study was the largest UK real world evidence study in CML patients who had been sequenced to a 3rd line tyrosine kinase inhibitor (TKI) and beyond.
- It is the first time all 5 TKIs have been studied in a UK real world setting.
- Ultimately, it was found that 69% of patients achieved a meaningful clinical outcome (major molecular response) when sequenced to line 3 and further.
View the abstract here.
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at firstname.lastname@example.org.